$3.41
1.49% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US8051111016
Symbol
SVRA
Sector
Industry

Savara, Inc. Stock price

$3.41
-0.07 2.01% 1M
-0.67 16.42% 6M
-1.29 27.45% YTD
-0.35 9.31% 1Y
+2.22 186.55% 3Y
+2.36 224.76% 5Y
-29.85 89.75% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.05 1.49%
ISIN
US8051111016
Symbol
SVRA
Sector
Industry

Key metrics

Market capitalization $585.22m
Enterprise Value $392.49m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.92
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-89.65m
Free Cash Flow (TTM) Free Cash Flow $-81.47m
Cash position $219.44m
EPS (TTM) EPS $-0.44
P/E forward negative
Short interest 9.61%
Show more

Is Savara, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Savara, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Savara, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Savara, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Savara, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.27 0.27
80% 80%
-
-0.27 -0.27
80% 80%
-
- Selling and Administrative Expenses 22 22
57% 57%
-
- Research and Development Expense 67 67
72% 72%
-
-89 -89
68% 68%
-
- Depreciation and Amortization 0.27 0.27
80% 80%
-
EBIT (Operating Income) EBIT -90 -90
68% 68%
-
Net Profit -83 -83
70% 70%
-

In millions USD.

Don't miss a Thing! We will send you all news about Savara, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Savara, Inc. Stock News

Neutral
Business Wire
4 days ago
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to four new employees. On November 20, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement award...
Neutral
Business Wire
4 days ago
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that an encore presentation of results from the pivotal, Phase 3 IMPALA-2 trial will be presented at the British Thoracic Society (BTS) Winter Meeting, taking place November 27-29, 2024, in London, England. BTS Platform Prese...
Neutral
Business Wire
22 days ago
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Guggenheim Inaugural Healthcare Conference on November 12, 2024 at 10:00am PT/1:00pm ET. A live webcast and subsequent replay of the fireside chat will be av...
More Savara, Inc. News

Company Profile

Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.

Head office United States
CEO Matthew Pauls
Employees 37
Founded 1995
Website www.savarapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today